2014

Reportlinker Adds The Cancer Market Outlook to 2015: Competitive landscape, market size, pipeline analysis, and growth opportunities

NEW YORK, Sept. 7 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Cancer Market Outlook to 2015: Competitive landscape, market size, pipeline analysis, and growth opportunities

http://www.reportlinker.com/p0172209/The-Cancer-Market-Outlook-to-2015-Competitive-landscape-market-size-pipeline-analysis-and-growth-opportunities.html

Global cancer prevalence rates are on the rise owing to an aging population, changing lifestyle and increasing pollution. Prevalence data is significantly influenced by the increasing diagnosis and survival rates across the global market.

The global cancer market is becoming increasingly competitive, with two therapeutic classes namely antineoplastics and cytostatic hormonal treatments dominating this sector. Collectively, the top 10 products in the global cancer market accounted for majority of the revenue in 2009.

Oncology has become one of the major focus areas for pharmaceutical and biotechnology companies because of a high number of unmet needs for improved treatments in different types of cancer. In 2009, around 40,000 Phase I, II and III trials were listed on ClinicalTrials.gov, and approximately 40% of these were related to cancer.

Targeted therapies are revolutionizing the paradigm of cancer treatment and are likely to be used in most cancer patients in the next 10 years. Due to the high incidence and subsequent potential for market success, breast cancer and NSCLC continue to drive high levels of R&D (along with niche indications such as NHL, RCC, CML, and prostate cancer).

Another factor that plays a major role for the growth in the cancer therapy market is expansion of the target indications. Most of the blockbuster drugs were launched for a narrow indication, and were later approved for other indications. A classic example is imatinib, which was first approved by the FDA in 2001 for the treatment of CML and later was expanded to around nine different indications.

Regardless of indication, the key challenge in ensuring the commercial success of pipeline drugs is to ascertain their integration into current treatment regimens either in combination with existing therapies or by demonstrating significant superiority over current treatments. Pricing risk remains the key investment concern in cancer. Moreover, the level of scrutiny by payors regarding the cost-effectiveness of cancer treatments has further intensified in the recent years.

Key Features of this report

• Epidemiological analysis and forecast prevalence of the major cancer indications between 2009-15 including lung, breast, colorectal, and ovarian cancer markets.

• Forecasts and analysis of the major products in the cancer market between 2009-15 spread across the major indications and classes of treatments.

• Overview of key events in the global cancer market that have impacted treatment trends and sales potential across the major cancer indications.

• Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios.

• Detailed analysis across major classes of cancer treatments including antineoplastics and cytotoxic hormone therapies.

• Detailed analysis of the clinically differentiated products in the cancer pipeline by indication and sales forecast of key R&D pipeline products in the global cancer market.

Key Benefits of this report

• Develop insight into patient potential with the report's coverage of major indications in the cancer segment, the seven largest geographic pharmaceutical markets and the 10 largest companies active in the cancer segment today

• Understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in the cancer marketplace

• Gain up-to-date competitive intelligence across the cancer indications and understand the major issues affecting key pharmaceutical/biotech players

• Understand which indications have the greatest potential to provide franchise growth, and how pharmaceutical companies are attempting to exploit these opportunities

• Compare the franchises of top pharmaceutical marketers across major indications, and understand how market share of leading companies will change over the next 6 years

• Use head-to head comparisons of the leading cancer pipeline compounds to understand which companies will have a presence among key indications over the next 6 years

Key findings of this report

The global cancer market in 2009 was valued at around $50bn, an increase of nearly 6% over previous year sales, and is forecast to grow at a CAGR of more than 7% between 2009–15.

Antineoplastics formed the leading drug class for cancer treatment. While competition is strong within the antineoplastic market, four drugs dominated the global antineoplastics market – Roche's Avastin (bevacizumab), MabThera (rituximab), and Herceptin (trastuzumab), and Novartis's Glivec (imatinib).

Cytostatic hormone therapies formed the other major drug class in the global cancer market, which was led by cytostatic aromatase inhibitors, cytostatic gonad hormone analogs and cytostatic anti-androgens. Arimidex and Femara remained the leading drugs in cytostatic hormone therapy registering Y-o-Y growth of around 3% and 15% respectively in 2009.

In 2009, monoclonal antibodies (mAbs) accounted for the majority of sales, achieving almost 30% share among the top 10 brands in the global cancer market. This was largely driven by the commercial success of the mAb brands: MabThera, Avastin, and Herceptin.

Roche was the leading player in the cancer market in 2009, with its leading products Avastin, MabThera, Herceptin, Tarceva and Xeloda.

Although a large number of cancer vaccines are in development, Dendreon's Provenge (sipuleucel-T) is the first therapeutic cancer vaccine which was approved in the US (April 2010) for the treatment of prostate cancer.

The top 10 true generic players in the cancer market represented 70% of the total generic market in 2009. Teva followed by Hospira remained the market leaders in the generic cancer market.

Key questions answered by this report

• What will be the major growth indications and the accompanying growth drivers in the cancer market over the next 6 years?

• Who were the leading players in the cancer market in 2009?

• Which products will be the future growth drivers for the cancer market?

• Which therapeutic categories are forecast to have the highest levels of commercial potential over the period 2009–15?

• Which indications are forecast to have the highest levels of market potential over the period 2009–15?

• What is the competitive landscape of key therapeutic areas?

• Which companies are best positioned to succeed in the cancer market over the period 2009–15?

• What are the significant market and pipeline developments that may shape corporate strategies for leading drug majors in this market?

• How is the generic market performing?

• How are the top 10 generic players positioned in the cancer market?

About Business Insights 2

Disclaimer 2

Executive summary 15

Overview and epidemiology of cancer indications 15

Global market analysis 16

Pipeline analysis 16

Competitive landscape 17

Chapter 1 Scope and methodology 19

Scope 19

Key cancer indications covered in this report 19

Methodology 20

Chapter 2 Overview and epidemiology of cancer indications 21

Summary 21

Introduction 22

Overview 22

Cancer risk factors 22

Lung cancer 24

Overview 24

Diagnosis, treatment and management 25

Epidemiology 26

NSCLC 26

SCLC 27

Forecast epidemiology 28

NSCLC 28

SCLC 29

Colorectal cancer 31

Overview 31

Diagnosis, treatment and management 31

Epidemiology 32

Forecast epidemiology 33

Breast cancer 35

Overview 35

Diagnosis, treatment and management 35

Epidemiology 36

Forecast epidemiology 37

Ovarian cancer 39

Overview 39

Diagnosis, treatment and management 40

Epidemiology 40

Forecast epidemiology 41

Uterine and cervical cancer 43

Overview 43

Diagnosis, treatment and management 43

Epidemiology 44

Forecast epidemiology 44

Leukemia 46

Overview 46

Diagnosis, treatment and management 47

Epidemiology 47

Forecast epidemiology 48

Prostate cancer 50

Overview 50

Diagnosis, treatment and management 50

Epidemiology 51

Forecast epidemiology 52

Pancreatic cancer 54

Overview 54

Diagnosis, treatment and management 54

Epidemiology 55

Forecast epidemiology 55

Lymphomas 57

Overview 57

Diagnosis, treatment and management 57

Epidemiology 58

Forecast epidemiology 59

Head and neck cancer 61

Overview 61

Diagnosis, treatment and management 62

Epidemiology 63

Forecast epidemiology 63

Chapter 3 Global market analysis 65

Summary 65

Introduction 65

Market analysis by country 66

Market analysis by drug class 68

Leading brand dynamics 69

Avastin (bevacizumab) – Roche 70

MabThera (rituximab) – Roche 72

Herceptin (trastuzumab) – Roche 73

Glivec/Gleevec (imatinib) – Novartis 74

Taxotere (docetaxel) – Sanofi-Aventis 75

Leading brands by type of cancer 76

Key recent events in the cancer market 79

Antineoplastics 82

Competitive dynamics of antineoplastics 82

Leading antineoplastic brands 84

Antineoplastic mAb market analysis 85

Market dynamics 85

Key brands analysis 85

Antineoplastic protein kinase inhibitors 87

Market dynamics 87

Key brands analysis 87

Vinca alkaloid market analysis 88

Market dynamics 88

Key brands analysis 88

Anti-metabolites 88

Market dynamics 88

Key brands analysis 89

Platinum compounds 89

Market dynamics 89

Key brands analysis 89

Antineoplastic sales forecast 90

Cytostatic hormonal therapies 91

Competitive dynamics of cytostatic hormonal therapies 91

Leading brands of cytostatic hormonal therapies 92

Cytostatic aromatase inhibitors market analysis 93

Market dynamics 93

Key brands analysis 94

Cytostatic gonadotrophin-releasing hormone analog market analysis 95

Market dynamics 95

Key brands analysis 95

Cytostatic anti-androgens 96

Market dynamics 96

Key brands analysis 96

Cytostatic hormonal therapy sales forecast 97

Global cancer market sales forecast 98

Generic cancer market 99

Chapter 4 Pipeline analysis 103

Summary 103

Introduction 104

Key trends in R&D 104

Targeted therapies are changing the treatment regimen of cancer 104

Cancer vaccines enhance the body's immune response 105

Pricing is becoming a major issue for cancer patients 105

Combination treatments are becoming the treatment of choice 106

Oncology pipeline 107

Leading drugs in development 108

Recently approved/marketed drugs 110

Afinitor (everolimus) – Novartis 110

Arzerra (ofatumumab) – GSK/Genmab 111

Votrient (pazopanib) – GSK 114

Provenge (sipuleucel-T) – Dendreon 116

Trastuzumab-DM1 (T-DM1) – Roche 117

Phase III compounds 120

Stimuvax (emepepimut- S) – Merck Serono 120

Ipilimumab (MDX-010) – Bristol Myers Squib (BMS) 122

Omnitarg (pertuzumab) – Roche 124

Abiraterone – Johnson & Johnson (J&J) 126

BSI-201(iniparib) – Sanofi-Aventis 128

Pipeline forecast of leading drugs in development 130

Factors affecting forecasts 130

Chapter 5 Competitive landscape 131

Summary 131

Introduction 132

Sales performance of leading players 132

Roche 134

Sales focus by drug class 135

Regional sales distribution 135

Marketed product portfolio 136

Pipeline analysis 138

Strategic and growth analysis 140

Drivers of growth 140

Resistors of growth 141

Novartis 142

Sales focus by drug class 142

Regional sales distribution 143

Marketed product portfolio 144

Pipeline analysis 145

Strategic and growth analysis 147

Drivers of growth 147

Resistors of growth 147

Sanofi-Aventis 148

Sales focus by drug class 148

Regional sales distribution 149

Marketed product portfolio 150

Pipeline analysis 151

Strategic and growth analysis 153

Drivers of growth 153

Resistors of growth 154

AstraZeneca 154

Sales focus by drug class 154

Regional sales distribution 155

Marketed products portfolio 156

Pipeline analysis 157

Strategic and growth analysis 158

Drivers of growth 158

Resistors of growth 159

Eli Lilly 160

Sales focus by drug class 160

Regional sales distribution 160

Marketed products portfolio 161

Pipeline analysis 162

Strategic and growth analysis 163

Drivers of growth 163

Resistors of growth 164

Competitive positioning of top true generic players in the cancer market 165

Appendix 167

IMS data 167

Antineoplastic and immunomodulating agents 167

L1: Antineoplastics 167

L2: Cytostatic hormone therapy 167

Forecast factors 167

Epidemiology forecast: 167

Market forecast: 167

Glossary 168

Abbreviations 168

Trial expansions 171

Table of figures

Figure 1: Treatment of lung cancer by stage 25

Figure 2: Types of breast cancers 35

Figure 3: Types of leukemia 46

Figure 4: Chemotherapy options for Hodgkin's disease 58

Figure 5: Head and neck cancers and their risk factors 62

Figure 6: 7MM cancer market share by region (%), 2009 67

Figure 7: Relative positions of the 7MM in the global cancer market, 2009 68

Figure 8: Current pharmacological treatment options for cancer 107

Figure 9: Oncology pipeline by indication and stage of development, 2010 108

Figure 10: Key drugs in late-stage development or that have been recently launched 109

Figure 11: Contribution of the top 10 players to growth of the global cancer market, 2008–09134

Figure 12: Roche's cancer sales by drug class ($m), 2009 135

Figure 13: Novartis' cancer sales by drug class ($m), 2009 143

Figure 14: Sanofi-Aventis' cancer sales by drug class ($m), 2009 149

Figure 15: AstraZeneca's cancer sales by drug class ($m), 2009 155

Figure 16: Competitive positioning of the top 10 true generic players in the 7MM, 2009 166

Table of tables

Table 1: Estimated prevalence of NSCLC across the seven major markets, 2009 27

Table 2: Estimated prevalence of SCLC across the seven major markets, 2009 28

Table 3: Forecast epidemiology of NSCLC across the seven major markets, 2009-15 29

Table 4: Forecast epidemiology of SCLC across the seven major markets, 2009-15 30

Table 5: Estimated prevalence of colorectal cancer across the seven major markets, 2009 33

Table 6: Forecast epidemiology of colorectal cancer across the seven major markets, 2009-15 34

Table 7: Estimated prevalence of breast cancer across the seven major markets, 2009 37

Table 8: Forecast epidemiology of breast cancer across the seven major markets, 2009-15 38

Table 9: Estimated prevalence of ovarian cancer across the seven major markets, 2009 41

Table 10: Forecast epidemiology of ovarian cancer across the seven major markets, 2009-1542

Table 11: Estimated prevalence of uterine and cervical cancer across the seven major markets, 2009 44

Table 12: Forecast epidemiology of uterine and cervical cancer across the seven major markets, 2009-15 45

Table 13: Estimated prevalence of leukemia across the seven major markets, 2009 48

Table 14: Forecast epidemiology of leukemia across the seven major markets, 2009-15 49

Table 15: Estimated prevalence of prostate cancer across the seven major markets, 2009 52

Table 16: Forecast epidemiology of prostate cancer across the seven major markets, 2009-1553

Table 17: Estimated prevalence of pancreatic cancer across the seven major markets, 2009 55

Table 18: Forecast epidemiology of pancreatic cancer across the seven major markets, 2009-15 56

Table 19: Estimated prevalence of lymphomas across the seven major markets, 2009 59

Table 20: Forecast epidemiology of lymphomas across the seven major markets, 2009-15 60

Table 21: Estimated prevalence of head and neck cancers across the seven major markets, 2009 63

Table 22: Forecast epidemiology of head and neck cancers across the seven major markets, 2009-15 64

Table 23: Global cancer market by geography ($m), 2009 66

Table 24: Breakdown of the global cancer market by drug class($m), 2009 69

Table 25: Leading brands in the global cancer market ($m), 2009 70

Table 26: Leading brands in breast cancer ($m), 2009 77

Table 27: Leading brands in colon cancer ($m), 2009 77

Table 28: Leading brands in prostate cancer ($m), 2009 78

Table 29: Leading brands in lung cancer ($m), 2009 78

Table 30: Breakdown of the global antineoplastic market by drug class ($m), 2009 83

Table 31: Leading brands in global antineoplastics market ($m), 2009 84

Table 32: Antineoplastic sales forecast ($m), 2009-15 90

Table 33: Breakdown of the global cytostatic hormonal therapies by drug class ($m), 2009 92

Table 34: Leading brands in global cytostatic hormonal therapies market ($m), 2009 93

Table 35: Cytostatic hormonal therapy sales forecast ($m), 2009-15 98

Table 36: Global cancer market sales forecast ($m), 2009–15 99

Table 37: Classification of the generic cancer market in the 7MM ($m), 2009 100

Table 38: Breakdown of the true generics cancer market by drug class in the 7MM ($m), 2009 100

Table 39: Breakdown of the true generics cancer market by drug class in the 7MM, 2009 (mSU) 101

Table 40: Leading true generic cancer drugs in the 7MM ($m), 2009 102

Table 41: An overview of Afinitor 110

Table 42: An overview of Arzerra 111

Table 43: An overview of Votrient 114

Table 44: An overview of Provenge 116

Table 45: An overview of trastuzumab-DM1 117

Table 46: Key recent trials with trastuzumab-DM1 119

Table 47: An overview of Stimuvax 120

Table 48: An overview of ipilimumab 122

Table 49: Key recent trials with ipilimumab 123

Table 50: An overview of Omnitarg 124

Table 51: Key recent trials with Omnitarg 125

Table 52: An overview of abiraterone 126

Table 53:Key recent trials with abiraterone 127

Table 54: An overview of BSI-201 128

Table 55: Sales forecast for leading drugs in development ($m), 2009–15 130

Table 56: Leading players in the global cancer market ($m), 2009 132

Table 57: Regional sales distribution of Roche ($m), 2009 136

Table 58: Roche's leading cancer products ($m), 2009 137

Table 59: Roche's late-stage cancer R&D pipeline, April 2010 139

Table 60: Regional sales distribution of Novartis ($m), 2009 144

Table 61: Novartis' leading cancer products ($m), 2009 145

Table 62: Novartis' late-stage cancer R&D pipeline, July 2010 146

Table 63: Regional sales distribution of Sanofi-Aventis ($m), 2009 150

Table 64: Sanofi-Aventis' leading cancer products ($m), 2009 151

Table 65: Sanofi-Aventis' late-stage cancer R&D pipeline, April 2010 152

Table 66: Regional sales distribution of AstraZeneca ($m), 2009 156

Table 67: AstraZeneca's leading cancer products ($m), 2009 157

Table 68: AstraZeneca's late-stage cancer R&D pipeline, April 2010 158

Table 69: Regional sales distribution of Eli Lilly ($m), 2009 161

Table 70: Eli Lilly's leading cancer products ($m), 2009 162

Table 71: Eli Lilly's late-stage cancer R&D pipeline, April 2010 163

Table 72: Leading true generic players in the 7MM cancer market ($m), 2009 165

To order this report:

Pharmaceutical Industry: The Cancer Market Outlook to 2015: Competitive landscape, market size, pipeline analysis, and growth opportunities

Pharmaceutical Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.